Key result
A systematic review of 10 studies demonstrated that SSRI use in patients undergoing cardiac surgery was not associated with significant differences in mortality or bleeding events.
Why the study?
Does selective serotonin re-uptake inhibitor use increase mortality, major adverse events, or bleeding events in patients undergoing cardiac surgery?
Systematic Review
Does selective serotonin re-uptake inhibitor use increase mortality, major adverse events, or bleeding events in patients undergoing cardiac surgery?
SSRI use appears safe in patients undergoing cardiac surgery, with no significant increase in mortality or bleeding events.
Answers are grounded in this paper and cite their sources.
Supports SSRI continuation around cardiac surgery; reinforces safety data from ten reviewed studies.
A high prevalence of depression is observed in patients undergoing cardiac surgery, and depression has been shown to be an independent predictor of morbidity and mortality in this patient population. Selective serotonin re-uptake inhibitors (SSRIs) are the first-line recommended therapy for depressive disorders, however due to their platelet inhibitory actions they have been associated with increased incidences of post-operative bleeding. This review has sought to address whether the use of SSRIs is associated with a higher rate of mortality, major adverse events or bleeding events following cardiac surgery. A retrospective literature search selected studies comparing the use of SSRIs with no SSRI use in patients undergoing cardiac surgery. Seven of the ten studies analysed reported no significant difference in mortality in SSRI users. Five of the seven studies reporting bleeding events demonstrated no significant difference in SSRI users. Three of the five studies reporting other significant morbidity demonstrated no significant difference in SSRI users. Our study demonstrates the safety of the use of SSRIs for the treatment of depressive disorders in patients undergoing cardiac surgery.
No takes yet. Share an insight, caveat, or question.
Sepehripour et al. (2018) conducted a systematic review in Cardiac surgery. Selective serotonin reuptake inhibitors (SSRIs) vs. No SSRI use was evaluated on Mortality, major adverse events, or bleeding events. A systematic review of 10 studies demonstrated that SSRI use in patients undergoing cardiac surgery was not associated with significant differences in mortality or bleeding events.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: